ArticleLangenbeck's archives of surgery2026
A predictive model for metastatic colorectal cancer based on immune cells and tumor markers.
Article in Langenbeck's archives of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study aims to investigate the relationship between immune cell levels, tumor markers, and metastatic colorectal cancer (mCRC), evaluate their predictive efficacy, and construct a predictive model.
methodRetrospectively selected patients diagnosed with colorectal cancer (CRC) through pathological examination at Shanxi Cancer Hospital between January 2016 and December 2018. T-tests and chi-square tests were used to identify clinical and pathological characteristics associated with mCRC. Evaluate predictive performance using the ROC curve. A risk factor scoring system is constructed based on immune cell levels and tumor markers, categorizing patients into low-risk and high-risk groups according to their scores. Single-factor and multi-factor logistic regression analyses were employed to identify independent predictors and construct a nomogram.
resultsA total of 270 patients with CRC were included, including 45 cases of mCRC. Statistical analysis results indicate that peripheral blood laboratory indicators associated with mCRC include immune cell levels (Th, Tc, Th/Tc) and tumor markers (CEA, CA199, CA242, CA724, CA50). The risk factor scoring system revealed that the incidence of distant metastasis was significantly higher in the high-risk group than in the low-risk group (P < 0.001). Furthermore, logistic regression analysis results indicate that the risk factor score is an independent predictor of distant metastasis in CRC.
conclusionA risk factor scoring system based on immune cell levels (Th, Tc, Th/Tc) and tumor markers (CEA, CA199, CA242, CA724, CA50) effectively predicts the occurrence of mCRC. This approach holds promise as a non-invasive tool for dynamic monitoring of distant metastasis risk in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.